304 results on '"Cohen, R. B."'
Search Results
2. Being mindful of our insomnia can get us to sleep? - Mindfulness aproach to sleep disorders
3. The new international division of labor, multinational corporations and urban hierarchy
4. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
5. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
6. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
7. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
8. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
9. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
10. State-selected reactive scattering. II. He+H+2→HeH++H.
11. Survey of chemi-ionization reactions in accelerated atom-O2 crossed-molecular beams.
12. Chemi-ionization reactions in accelerated uranium-O2 crossed molecular beams.
13. Dynamics of flame propagation using laser-induced spark initiation: Ignition energy measurements.
14. The Influence of Pathologic Features on Clinical Outcome of Breast Cancer Patients Treated by Primary Radiation Therapy
15. Collinear reactive scattering of state-selected H+2+He→HeH++H: A method for probing dynamical resonances.
16. Histochemical Observations on Carbohydrate Metabolism in the Adrenal Cortex of the Rat, with Special Reference to Stress and Sodium Depletion
17. SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data
18. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
19. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
20. Analysis of p16 expression by AQUA in non-small cell lung cancer (NSCLC) among non-smokers.
21. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
22. Identification of barriers to clinical trials: The impact of education level.
23. Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
24. ChemInform Abstract: Photochemistry of Sulfide Dimer Cations in Clusters of Dimethyl Sulfide.
25. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.
26. Phase I study of PF-03446962, a fully human mab against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
27. Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.
28. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
29. Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297.
30. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.
31. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
32. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.
33. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors.
34. Results of a phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies
35. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN)
36. Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results
37. Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors
38. First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors
39. Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors
40. Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
41. Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs)
42. Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
43. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
44. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers
45. Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase
46. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
47. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies
48. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors
49. A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer
50. Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.